10:42 AM EST, 11/10/2025 (MT Newswires) -- AnaptysBio ( ANAB ) said Monday its phase 2 trial of rosnilimab in ulcerative colitis failed to meet its primary endpoint and key secondary goals.

The placebo-controlled study evaluated rosnilimab in patients with moderate-to-severe ulcerative colitis, a chronic inflammatory disease of the colon.

Data show that rosnilimab was safe and well tolerated; however, it did not meet its main goal of improving the modified Mayo Score, a standard measure of disease activity in ulcerative colitis, or its key secondary endpoints of clinical response and clinical remission after 12 weeks of treatment.

Placebo rates in the study were within expected historical ranges, the company said.

AnaptysBio ( ANAB ) said it will discontinue the ulcerative colitis trial, a move expected to save at least $10 million.

Shares of AnaptysBio ( ANAB ) fell nearly 14% in recent trading.

Price: 34.23, Change: -5.43, Percent Change: -13.68